2026 / 03

Следующая статья
DOI: 10.24075/vrgmu.2026.035
Авторские права: © 2026 принадлежат авторам. Лицензиат: РНИМУ им. Н.И. Пирогова.
Статья размещена в открытом доступе и распространяется на условиях лицензии Creative Commons Attribution (CC BY).

ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ

Влияние нокаута гена β-аррестина 2 на провоспалительный статус мышей в условиях стрептозотоцин-вызванного сахарного диабета

А. А. Волкова1,2 , А. С. Гладкова2
Информация об авторах

1 Институт физиологии, Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва, Россия

2 Биологический факультет, Московский государственный университет имени М. В. Ломоносова, Москва, Россия

Для корреспонденции: Анна Александровна Волкова
ул. Островитянова, д. 1, г. Москва, 117997; ur.umsr@4aa_avoklov

Информация о статье

Финансирование: работа поддержана грантом РНФ №24-75-00164 «Роль бета-аррестина в развитии ишемии мозга на фоне сахарного диабета у мышей».

Вклад авторов: А. А. Волкова — идея работы и планирование эксперимента, сбор и обработка данных, написание и редактирование статьи; А. С. Гладкова — сбор и обработка данных, написание и редактирование статьи.

Соблюдение этических стандартов: исследование одобрено этическим комитетом Российского национального исследовательского медицинского университета имени Н. И. Пирогова (протокол № 23/2021 от 13 декабря 2021 г.). Все процедуры, выполненные в исследованиях с участием животных, соответствовали этическим стандартам, утвержденным правовыми актами РФ, принципам Базельской декларации.

Статья получена: 14.04.2026 Статья принята к печати: 30.04.2026 Опубликовано online: 27.06.2026
|
  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet (London, England). 2024; 404: 2077–93. Available from: https://doi.org/10.1016/S0140-6736(24)02317-1.
  2. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Kutakova DV, et al. Epidemiology and key clinical and therapeutic indicators of diabetes mellitus in Russian Federation according to the World Health Organization’s strategy goals. Diabetes Mellit. 2025; 28: 4–17. Available from: https://doi.org/10.14341/DM13292.
  3. Mosenzon O, Cheng AY, Rabinstein AA, Sacco S. Diabetes and Stroke: What Are the Connections? J Stroke. 2023; 25: 26–38. Available from: https://doi.org/10.5853/jos.2022.02306.
  4. Szablewski L. Associations Between Diabetes Mellitus and Neurodegenerative Diseases. Int J Mol Sci. 2025; 26: 542. Available from: https://doi.org/10.3390/ijms26020542.
  5. Rocha KMA, Goulart A da S, Costa MT, Salgueiro ACF, Folmer V. The role of type 2 Diabetes mellitus as a risk factor for Alzheimer’s and Parkinson’s diseases. Res Soc Dev. 2021; 10: e23410111673. Available from: https://doi.org/10.33448/rsd-v10i1.11673.
  6. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022; 55 : 31–55. Available from: https://doi.org/10.1016/j.immuni.2021.12.013.
  7. González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int J Mol Sci/ 2023; 24: 9352. Available from: https://doi.org/10.3390/ijms24119352.
  8. Dong H, Zhang Y, Huang Y, Deng H. Pathophysiology of RAGE in inflammatory diseases. Front Immunol. 2022; 13. Available from: https://doi.org/10.3389/fimmu.2022.931473.
  9. Ighodaro OM. Molecular pathways associated with oxidative stress in diabetes mellitus. Biomed Pharmacother. 2018; 108: 656–62. Available from: https://doi.org/10.1016/j.biopha.2018.09.058.
  10. Yaribeygi H, Atkin SL, Sahebkar A. A review of the molecular mechanisms of hyperglycemia‐induced free radical generation leading to oxidative stress. J Cell Physiol. 2019; 234: 1300–12. Available from: https://doi.org/10.1002/jcp.27164.
  11. Nedosugova LV, Markina YV, Bochkareva LA, Kuzina IA, Petunina NA, Yudina IY, et al. Inflammatory Mechanisms of Diabetes and Its Vascular Complications. Biomedicines. 2022; 10: 1168. Available from: https://doi.org/10.3390/biomedicines10051168.
  12. Takeda Y, Matoba K, Sekiguchi K, Nagai Y, Yokota T, Utsunomiya K, et al. Endothelial Dysfunction in Diabetes. Biomedicines. 2020; 8: 182. Available from: https://doi.org/10.3390/biomedicines8070182.
  13. Takata F, Nakagawa S, Matsumoto J, Dohgu S. Blood- Brain Barrier Dysfunction Amplifies the Development of Neuroinflammation: Understanding of Cellular Events in Brain Microvascular Endothelial Cells for Prevention and Treatment of BBB Dysfunction. Front Cell Neurosci. 2021; 15. Available from: https://doi.org/10.3389/fncel.2021.661838.
  14. Rom S, Zuluaga-Ramirez V, Gajghate S, Seliga A, Winfield M, Heldt NA, et al. Hyperglycemia-Driven Neuroinflammation Compromises BBB Leading to Memory Loss in Both Diabetes Mellitus (DM) Type 1 and Type 2 Mouse Models. Mol Neurobiol. 2019; 56: 1883–96. Available from: https://doi.org/10.1007/s12035-018-1195-5.
  15. Oliveira de Souza C, Sun X, Oh D. Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity. Front Endocrinol (Lausanne). 2021; 12. Available from: https://doi.org/10.3389/fendo.2021.715877.
  16. Wang H, Deng Q-W, Peng A-N, Xing F-L, Zuo L, Li S, et al. β-arrestin2 functions as a key regulator in the sympathetic-triggered immunodepression after stroke. J Neuroinflammation. 2018; 15: 102. Available from: https://doi.org/10.1186/s12974-018-1142-4.
  17. Qi M, Chen T, Li L, Gao P, Li N, Zhang S, et al. Insight into the regulatory mechanism of β ‐arrestin2 and its emerging role in diseases. Br J Pharmacol. 2024; 181: 3019–38. Available from: https://doi.org/10.1111/bph.16488.
  18. Gu Y, Sun W, Zhang S, Wu J, Wei W. The emerging roles of β-arrestins in fibrotic diseases. Acta Pharmacol Sin. 2015; 36: 1277–87. Available from: https://doi.org/10.1038/aps.2015.74.
  19. Zhu L, Almaça J, Dadi PK, Hong H, Sakamoto W, Rossi M, et al. β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions. Nat Commun. 2017; 8: 14295. Available from: https://doi.org/10.1038/ncomms14295.
  20. Fang Y, Jiang Q, Li S, Zhu H, Xu R, Song N, et al. Opposing functions of β-arrestin 1 and 2 in Parkinson’s disease via microglia inflammation and Nprl3. Cell Death Differ. 2021; 28: 1822–36. Available from: https://doi.org/10.1038/s41418-020-00704-9.
  21. Sun J, Lin X. β-Arrestin 2 is required for lysophosphatidic acid-induced NF-κB activation. Proc Natl Acad Sci. 2008; 105: 17085– 90. Available from: https://doi.org/10.1073/pnas.0802701105.
  22. Kim J, Zhang L, Peppel K, Wu J-H, Zidar DA, Brian L, et al. β-Arrestins Regulate Atherosclerosis and Neointimal Hyperplasia by Controlling Smooth Muscle Cell Proliferation and Migration. Circ Res. 2008; 103: 70–9. Available from: https://doi.org/10.1161/CIRCRESAHA.108.172338.
  23. Galkov MD, Ivanova AE, Gulyaev MV, Kiseleva EV, Savinkova IG, Gorbacheva LR. The Influence of β-Arrestin-2 Gene Knockout in Mice on Survival of Cultured Astrocytes Exposed to Thrombin and on the Cerebral Thrombosis Aftereffects In Vivo. Biochem (Moscow), Suppl Ser A Membr Cell Biol. 2020; 14: 17–23. Available from: https://doi.org/10.1134/S1990747819060060.
  24. Santos EW, Oliveira DC de, Hastreiter A, Silva GB da, Beltran JS de O, Tsujita M, et al. Hematological and biochemical reference values for C57BL/6, Swiss Webster and BALB/c mice. Brazilian J Vet Res Anim Sci. 2016; 53: 138. Available from: https://doi.org/10.11606/issn.1678-4456.v53i2p138-145.
  25. Furman BL. Streptozotocin‐Induced Diabetic Models in Mice and Rats. Curr Protoc. 2021; 1. Available from: https://doi.org/10.1002/cpz1.78.
  26. Ravier MA, Leduc M, Richard J, Linck N, Varrault A, Pirot N, et al. β-Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in mice. Diabetologia. 2014; 57: 532–41. Available from: https://doi.org/10.1007/s00125-013-3130-7.
  27. Goyal SN, Reddy NM, Patil KR, Nakhate KT, Ojha S, Patil CR, et al. Challenges and issues with streptozotocin-induced diabetes — A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem Biol Interact. 2016; 244: 49–63. Available from: https://doi.org/10.1016/j.cbi.2015.11.032.
  28. Du J, Sun J, Li N, Li X, Sun W, Wei W. β-Arrestin2 deficiency attenuates oxidative stress in mouse hepatic fibrosis through modulation of NOX4. Acta Pharmacol Sin. 2021; 42: 1090–100. Available from: https://doi.org/10.1038/s41401-020-00545-9.
  29. Elksnis A, Welsh N, Wikström P, Lau J, Carlsson P-O. The selective NOX4 inhibitor GLX7013159 decreases blood glucose concentrations and human beta-cell apoptotic rates in diabetic NMRI nu/nu mice transplanted with human islets. Free Radic Res. 2023: 1–10. Available from: https://doi.org/10.1080/10715762.2023.2284637.
  30. Elksnis A, Cen J, Wikström P, Carlsson P-O, Welsh N. Pharmacological Inhibition of NOX4 Improves Mitochondrial Function and Survival in Human Beta-Cells. Biomedicines. 2021; 9: 1865. Available from: https://doi.org/10.3390/biomedicines9121865.
  31. Pang Y, Zhu H, Xu J, Yang L, Liu L, Li J. β-arrestin-2 is involved in irisin induced glucose metabolism in type 2 diabetes via p38 MAPK signaling. Exp Cell Res. 2017; 360: 199–204. Available from: https://doi.org/10.1016/j.yexcr.2017.09.006.
  32. Ou Y, Zheng Z, Niu B, Su J, Su H. Different MAPK signal transduction pathways play different roles in the impairment of glucose stimulated insulin secretion in response to IL 1β. Mol Med Rep. 2020. Available from: https://doi.org/10.3892/mmr.2020.11366.
  33. Fukuda K, Tesch GH, Yap FY, Forbes JM, Flavell RA, Davis RJ, et al. MKK3 signalling plays an essential role in leukocyte-mediated pancreatic injury in the multiple low-dose streptozotocin model. Lab Investig. 2008; 88: 398–407. Available from: https://doi.org/10.1038/labinvest.2008.10.
  34. Su Y, Raghuwanshi SK, Yu Y, Nanney LB, Richardson RM, Richmond A. Altered CXCR2 Signaling in β-Arrestin-2-Deficient Mouse Models. J Immunol. 2005; 175: 5396–402. Available from: https://doi.org/10.4049/jimmunol.175.8.5396.
  35. Pydi SP, Barella LF, Meister J, Wess J. Key Metabolic Functions of β-Arrestins: Studies with Novel Mouse Models. Trends Endocrinol Metab. 2021; 32: 118–29. Available from: https://doi.org/10.1016/j.tem.2020.11.008.
  36. Gargiulo S, Gramanzini M, Megna R, Greco A, Albanese S, Manfredi C, et al. Evaluation of Growth Patterns and Body Composition in C57Bl/6J Mice Using Dual Energy X-Ray Absorptiometry. Biomed Res Int. 2014; 2014: 1–11. Available from: https://doi.org/10.1155/2014/253067.
  37. Laboratory TJ. Body Weight Information for C57BL/6J. 2026. Available from: https://www.jax.org/jax-mice-and-services/strain-data-sheet-pages/body-weight-chart-000664.
  38. Feng M, Wang R, Deng L, Yang Y, Xia S, Liu F, et al. Arrestin beta- 2 deficiency exacerbates periodontal inflammation by mediating activating transcription factor 6 activation and abnormal remodelling of the extracellular matrix. J Clin Periodontol. 2024; 51: 742–53. Available from: https://doi.org/10.1111/jcpe.13952.
  39. Sharma D, Parameswaran N. Multifaceted role of β-arrestins in inflammation and disease. Genes Immun. 2015; 16: 499–513. Available from: https://doi.org/10.1038/gene.2015.37.
  40. Hatanaka E, Monteagudo PT, Marrocos MSM, Campa A. Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. Clin Exp Immunol. 2006; 146: 443–7. Available from: https://doi.org/10.1111/j.1365-2249.2006.03229.x.
  41. Pettersson US, Christoffersson G, Massena S, Ahl D, Jansson L, Henriksnäs J, et al. Increased Recruitment but Impaired Function of Leukocytes during Inflammation in Mouse Models of Type 1 and Type 2 Diabetes. PLoS One. 2011; 6: e22480. Available from: https://doi.org/10.1371/journal.pone.0022480.
  42. Harsunen M, Puff R, D’Orlando O, Giannopoulou E, Lachmann L, Beyerlein A, et al. Reduced Blood Leukocyte and Neutrophil Numbers in the Pathogenesis of Type 1 Diabetes. Horm Metab Res. 2013; 45: 467–70. Available from: https://doi.org/10.1055/s-0032-1331226.
  43. Fang X, Dorcely B, Ding X, Yin S, Son N-H, Hu S-L, et al. Glycemic reduction alters white blood cell counts and inflammatory gene expression in diabetes. J Diabetes Complications. 2018; 32: 1027– 34. Available from: https://doi.org/10.1016/j.jdiacomp.2018.08.003.
  44. Jiang M-P, Xu C, Guo Y-W, Luo Q-J, Li L, Liu H-L, et al. β-arrestin 2 attenuates lipopolysaccharide-induced liver injury via inhibition of TLR4/NF-κB signaling pathway-mediated inflammation in mice. World J Gastroenterol. 2018; 24: 216–25. Available from: https://doi.org/10.3748/wjg.v24.i2.216.
  45. Wang Y, Tang Y, Teng L, Wu Y, Zhao X, Pei G. Association of β-arrestin and TRAF6 negatively regulates Toll-like receptor– interleukin 1 receptor signaling. Nat Immunol. 2006; 7: 139–47. Available from: https://doi.org/10.1038/ni1294.
  46. Zhu J, Hu Z, Han X, Wang D, Jiang Q, Ding J, et al. Dopamine D2 receptor restricts astrocytic NLRP3 inflammasome activation via enhancing the interaction of β-arrestin2 and NLRP3. Cell Death Differ. 2018; 25: 2037–49. Available from: https://doi.org/10.1038/s41418-018-0127-2.
  47. Peach CJ, Edgington-Mitchell LE, Bunnett NW, Schmidt BL. Protease-activated receptors in health and disease. Physiol Rev. 2023; 103: 717–85. Available from: https://doi.org/10.1152/physrev.00044.2021.
  48. Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: Receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev. 2007; 56: 331–45. Available from: https://doi.org/10.1016/j.brainresrev.2007.08.002.
  49. Fong AM, Premont RT, Richardson RM, Yu YRA, Lefkowitz RJ, Patel DD. Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. Proc Natl Acad Sci USA. 2002; 99: 7478– 83. Available from: https://doi.org/10.1073/pnas.112198299.